Skip to main content
. Author manuscript; available in PMC: 2018 Apr 12.
Published in final edited form as: ACS Appl Mater Interfaces. 2017 Mar 28;9(14):12195–12202. doi: 10.1021/acsami.6b15987

Figure 3.

Figure 3

Trastuzumab corona increases uptake of colloids by HER2 overexpressing cells. (A) Trastuzumab-modified colloids (BODIPY, green), but not (B) IgG-modified colloids, are taken up by HER2 overexpressing SKOV-3 cells (blue, Hoechst for cell nuclei; red, wheat germ agglutinin for cell membranes) after a 3 h incubation. Neither (C) trastuzumab-modified nor (D) IgG-modified colloids are taken up by MDA-MB-231 cells that are HER2 low-expressing. Formulations used are 50 μM fulvestrant, 1% DMSO, and 3.5 μM antibody in 5% serum. Scale bars represent 50 μm. Representative confocal microscope images of at least three biological repeats.